Comparison of the Effectiveness of Monitoring Cisplatin-Induced Ototoxicity with Extended High-Frequency Pure-Tone Audiometry or Distortion-Product Otoacoustic Emission
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background and Objectives: To compare the effectiveness of monitoring cisplatin-induced ototoxicity in adult patients using extended high-frequency pure-tone audiometry (EHF-PTA) or distortion-product otoacoustic emission (DP-OAE) and to evaluate the concurrence of ototoxicity and nephrotoxicity in cisplatin-treated patients. Subjects and Methods: EHF-PTA was measured at frequencies of 0.25, 0.5, 1, 2, 3, 4, 6, 8, 9, 11.2, 12.5, 14, 16, 18, and 20 kHz and DP-OAE at frequencies of 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, and 8 kHz in cisplatin-treated patients (n=10). Baseline evaluations were made immediately before chemotherapy and additional tests were performed before each of six cycles of cisplatin treatment. Laboratory tests to monitor nephrotoxicity were included before every cycle of chemotherapy. Results: Four of 10 patients showed threshold changes on EHF-PTA. Five of 10 patients showed reductions in DP-OAE, but one was a false-positive result. The results of EHF-PTA and DP-OAE were consistent in two patients. Only one patient displayed nephrotoxicity on laboratory tests after the third cycle. Conclusions: In our study, the incidence rate of cisplatin-induced ototoxicity was 40% with EHF-PTA or DP-OAE. Although both EHF-PTA and DP-OAE showed the same sensitivity in detecting ototoxicity, they did not produce the same results in all patients. These two hearing tests could be used to complement one another. Clinicians should use both tests simultaneously in every cycle of chemotherapy to ensure the detection of ototoxicity
Abstract
Background and Objectives: To compare the effectiveness of monitoring cisplatin-induced ototoxicity in adult patients using extended high-frequency pure-tone audiometry (EHF-PTA) or distortion-product otoacoustic emission (DP-OAE) and to evaluate the concurrence of ototoxicity and nephrotoxicity in cisplatin-treated patients. Subjects and Methods: EHF-PTA was measured at frequencies of 0.25, 0.5, 1, 2, 3, 4, 6, 8, 9, 11.2, 12.5, 14, 16, 18, and 20 kHz and DP-OAE at frequencies of 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, and 8 kHz in cisplatin-treated patients (n=10). Baseline evaluations were made immediately before chemotherapy and additional tests were performed before each of six cycles of cisplatin treatment. Laboratory tests to monitor nephrotoxicity were included before every cycle of chemotherapy. Results: Four of 10 patients showed threshold changes on EHF-PTA. Five of 10 patients showed reductions in DP-OAE, but one was a false-positive result. The results of EHF-PTA and DP-OAE were consistent in two patients. Only one patient displayed nephrotoxicity on laboratory tests after the third cycle. Conclusions: In our study, the incidence rate of cisplatin-induced ototoxicity was 40% with EHF-PTA or DP-OAE. Although both EHF-PTA and DP-OAE showed the same sensitivity in detecting ototoxicity, they did not produce the same results in all patients. These two hearing tests could be used to complement one another. Clinicians should use both tests simultaneously in every cycle of chemotherapy to ensure the detection of ototoxicity
참고문헌 (30)
- Yilmaz S., "Detection of cisplatin-induced ototoxicity with transient evoked otoacoustic emission test before pure tone audiometer", Eur Arch Otorhinolaryngol, 267, pp.1041~1044 (2010)
- Lanvers-Kaminsky C., "Continuous or repeated prolonged cisplatin infusions in children : a prospective study on ototoxicity, platinum concentrations, and standard serum parameters", Pediatr Blood Cancer, 47, pp.183~193 (2006)
- Schaefer SD., "Ototoxicity of low-and moderate-dose cisplatin", Cancer, 56, pp.1934~1939 (1985)
- American Speech-Language-Hearing Association., "Guidelines for the audiologic management of individuals receiving cochleotoxic drug therapy", ASHA, 36, pp.11~19 (1994)
- Beattie RC., "Immediate and short-term reliability of distortion-product otoacoustic emissions", Int J Audiol, 42, pp.348~354 (2003)
- Eiamprapai P., "Effect of cisplatin on distortion product otoacoustic emissions in Japanese patients", Laryngoscope, 122, pp.1392~1396 (2012)
- Komune S., "Pathophysiology of the ototoxicity of cis-diamminedichloroplatinum", Otolaryngol Head Neck Surg, 89, pp.275~282 (1981)
- Brummett RE., "Drug-induced ototoxicity", Drugs, 19, pp.412~428 (1980)
- Nakai Y., "Ototoxicity of the anticancer drug cisplatin. An experimental study", Acta Otolaryngol, 93, pp.227~232 (1982)
- Konishi T., "Ototoxicity of cis-dichlorodiammine platinum(II. in guinea pigs", Am J Otolaryngol, 4, pp.18~26 (1983)
- Schweitzer VG., "Ototoxic and nephrotoxic effects of combined treatment with cis-diamminedichloroplatinum and kanamycin in the guinea pig", Otolaryngol Head Neck Surg, 92, pp.38~49 (1984)
- Arenberg IK., "Dizziness and Balance Disorders" (1993), Kugler Publications
- Coradini PP., "Ototoxicity from cisplatin therapy in childhood cancer", J Pediatr Hematol Oncol, 29, pp.355~360 (2007)
- Fausti SA., "High-frequency audiometric monitoring strategies for early detection of ototoxicity", Ear Hear, 15, pp.232~239 (1994)
- Knight KR., "Early changes in auditory function as a result of platinum chemotherapy : use of extended high-frequency audiometry and evoked distortion product otoacoustic emissions", J Clin Oncol, 25, pp.1190~1195 (2007)
- Littman TA., "Monitoring and predicting ototoxic damage using distortion-product otoacoustic emissions : pediatric case study", J Am Acad Audiol, 9, pp.257~262 (1998)
- Ress BD., "Effects of cis-platinum chemotherapy on otoacoustic emissions : the development of an objective screening protocol. Third place--Resident Clinical Science Award 1998", Otolaryngol Head Neck Surg, 121, pp.693~701 (1999)
- Stavroulaki P., "Evoked otoacoustic emissions--an approach for monitoring cisplatin induced ototoxicity in children", Int J Pediatr Otorhinolaryngol, 59, pp.47~57 (2001)
- Delehaye E., "Distortion-product otoacoustic emission : early detection in deferoxamine induced ototoxicity", Auris Nasus Larynx, 35, pp.198~202 (2008)
- Dhooge I., "Distortion product otoacoustic emissions : an objective technique for the screening of hearing loss in children treated with platin derivatives", Int J Audiol, 45, pp.337~343 (2006)
- Sakamoto M., "Extended high-frequency ototoxicity induced by the first administration of cisplatin", Otolaryngol Head Neck Surg, 122, pp.828~833 (2000)
- Reavis KM., "Factors affecting sensitivity of distortion-product otoacoustic emissions to ototoxic hearing loss", Ear Hear, 29, pp.875~893 (2008)
- Mukherjea D., "Expression of the kidney injury molecule 1 in the rat cochlea and induction by cisplatin", Neuroscience, 139, pp.733~740 (2006)
- de Jongh FE., "Weekly high-dose cisplatin is a feasible treatment option : analysis on prognostic factors for toxicity in 400 patients", Br J Cancer, 88, pp.1199~1206 (2003)
- Máthé C., "Cisplatin nephrotoxicity aggravated by cardiovascular disease and diabetes in lung cancer patients", Eur Respir J, 37, pp.888~894 (2011)
- Biro K., "Characteristics and risk factors of cisplatin-induced ototoxicity in testicular cancer patients detected by distortion product otoacoustic emission", Oncology, 70, pp.177~184 (2006)
- Osterhammel D., "High frequency audiometry. Clinical aspects", Scand Audiol, 9, pp.249~256 (1980)
- Kujansuu E., "Evaluation of the hearing loss associated with cis-platinum treatment by high-frequency audiometry", Gynecol Oncol, 33, pp.321~322 (1989)
- Lonsbury-Martin BL., "Evidence for the influence of aging on distortion-product otoacoustic emissions in humans", J Acoust Soc Am, 89(4 Pt 1), pp.1749~1759 (1991)
- Stover L., "The effects of aging on otoacoustic emissions", J Acoust Soc Am, 94, pp.2670~2681 (1993)